Advagene Biopharma Co (ROCO:6709) ROCE % : -85.69% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Advagene Biopharma Co's annualized ROCE % for the quarter that ended in Jun. 2023 was -85.69%.

Advagene Biopharma Co ROCE % Historical Data

The historical data trend for Advagene Biopharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co ROCE % Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-29.63

-24.36

-33.30

-61.52

-67.61

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial										-37.92	-49.95	-76.01	-85.69	-80.80

Advagene Biopharma Co ROCE % Calculation

Advagene Biopharma Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-92.074	/	( ( (140.838 - 8.423)	+	(147.934 - 7.972) )	/ 2 )
	=	-92.074	/	( (132.415	+	139.962)	/ 2 )
	=	-92.074	/	136.1885
	=	-67.61 %

Advagene Biopharma Co's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-93.21	/	( ( (140.838 - 8.423)	+	(93.904 - 8.771) )	/ 2 )
	=	-93.21	/	( ( 132.415	+	85.133 )	/ 2 )
	=	-93.21	/	108.774
	=	-85.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Advagene Biopharma Co (ROCO:6709) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Advagene Biopharma Co ROCE % Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines